CJC-1295 with DAC

Growth Hormone-Releasing Hormone Analog: CJC-1295 with DAC

CJC-1295 with DAC (Drug Affinity Complex) constitutes a manufactured peptide compound formulated as an improved variant of the naturally secreted growth hormone–releasing hormone (GHRH). The compound was engineered using molecular design principles aimed at circumventing rapid enzymatic degradation and extending the pharmacological activity period. The DAC modification facilitates attachment to serum albumin, thereby preventing both kidney filtration and enzymatic inactivation. This technology enables sustained activation of growth hormone release, providing a markedly superior activity profile in comparison to unmodified GHRH preparations.

Mechanistic Basis and Endocrine Regulation

CJC-1295 possessing a Drug Affinity Complex modification represents a synthetic, protracted-action variant of GHRH created to optimize chemical endurance and extend the stimulatory impact on GH secretion. The compound achieves its effects through interaction with GHRH receptors present on anterior pituitary somatotrophs, initiating signal transduction cascades that provoke pulsatile GH discharge mirroring natural hormonal patterns.

Upon its discharge into circulation, GH functions as a hormonal signal stimulating the synthesis and release of insulin-like growth factor-1 (IGF-1) from hepatic and peripheral tissues, with IGF-1 serving as the critical executor of growth-promoting metabolic activities, tissue regeneration, and cellular expansion. The tandem regulatory actions of GH and IGF-1 form the foundation of systemic metabolic control, adipose tissue lipolysis, and myofibrillar protein deposition. GH specifically exerts profound effects on the degradation of lipids within both deep and superficial adipose tissue while preserving muscle mass and contractile function.

A principal advantage imparted by DAC technology derives from the capacity of the modified peptide to establish persistent binding with serum albumin. Such interaction substantially extends the duration of the peptide's circulation and bioavailability, facilitating sustained target cell receptor occupancy and continuous GH discharge. Consequently, CJC-1295 with DAC retains measurable biological activity across extended periods of days to weeks post-administration—substantially surpassing the activity span of non-DAC variants including standard CJC-1295 or unaltered GHRH(1-29).

At the intracellular level, CJC-1295 interaction with the GHRH receptor presumably engages the cAMP biosynthetic pathway through adenylate cyclase stimulation. This cascade results in protein kinase A (PKA) mobilization, culminating in phosphorylation of regulatory nuclear proteins and heightened expression of GH-encoding genetic material within pituitary somatotrophs. The prolonged availability of the albumin-peptide complex sustains continual activation of this cascade, producing cumulative increases in GH output and elevated IGF-1 plasma concentrations compared to rapidly-eliminated peptide compounds.

Overall, CJC-1295 with DAC supplies a robust research instrument for probing sustained endocrine activation, elucidating how the GH/IGF-1 regulatory network operates, and measuring the physiological impact of continuous pulsatile GH secretion.

Chemical Identity and Molecular Structure

Physicochemical Properties

Appearance: Lyophilized white crystalline compound

Molecular Formula: C₁₆₅H₂₇₁N₄₇O₄₆

Molecular Weight: ~3647.9 g/mol

Peptide Sequence: Modified GHRH(1–29) with integrated DAC unit

Purity: Minimum 98% per Certificate of Analysis

CJC-1295 with DAC: Standard Laboratory Procedures

Storage Requirements and Environmental Maintenance

CJC-1295 with DAC is provided in sterile, lyophilized powder format designed for research settings. Preservation of both chemical structure and inherent biological activity requires storage at –20°C in the anhydrous powder state. Once reconstituted in aqueous medium, the peptide solution requires storage under strict sterile aseptic conditions at 2–8°C for limited-duration experimental use. These storage specifications guarantee the chemical architecture remains intact and substantially decrease the likelihood of degradation processes or introduction of contaminating microorganisms during experimental procedures.

GH Release Patterns and Circulating Elevations

Clinical human research and animal model systems have documented that a single dose of CJC-1295 with DAC induces sustained elevation in blood GH and IGF-1 extending for approximately one week. This extended hormonal response diverges significantly from the momentary elevations observed following administration of native GHRH(1-29) or non-DAC peptide formulations. Quantified results indicate IGF-1 concentration increases of approximately 2–3-fold concurrent with maintained pulsatile GH secretion patterns, substantiating potent receptor-mediated signal transduction and sustained circulation of the peptide.

Physiological and Metabolic Consequences

Investigation indicates that CJC-1295 with DAC exerts notable effects on overall metabolism, principally through elevation of circulating GH and IGF-1 concentrations. Preclinical observations report enhanced rates of lipolysis, superior capacity for fat oxidative metabolism, and maintenance of skeletal muscle tissue, all concordant with the established metabolic roles of GH. The compound has been assessed regarding effects on amino acid polymerization, accelerated restoration of damaged tissues, and alterations in thermogenic energy expenditure, providing utility for studying GH-regulated metabolic biology.

Extended Circulation Time and Prolonged Activity

Unlike shorter-lived GHRH peptides, CJC-1295's DAC component creates a robust peptide-albumin association, markedly reducing kidney-mediated elimination and enzymatic inactivation. This persistent binding between the peptide and albumin substantially extends the active lifetime within the circulatory system, perpetuating continuous receptor signaling and unrelenting GH stimulation. Kinetic analysis demonstrates a terminal half-life spanning approximately 5.8 to 8.1 days, substantially exceeding the minutes-to-hours elimination profile of non-albumin-binding peptide counterparts, thereby allowing less frequent dosing intervals in experimental designs.

Attribution and Scholarly Contributions

Compilation and Expert Curation

This scientific literature review has been painstakingly compiled, comprehensively reviewed, and systematically structured by Dr. Stuart L. Teichman, M.D. A distinguished authority in endocrinology and clinical investigation, Dr. Teichman has conducted landmark research into prolonged-acting GHRH analogs with particular focus on CJC-1295. His seminal publications have detailed the pharmacological attributes, safety characteristics, and therapeutic capabilities of GHRH peptide compounds, illuminating their capacity to generate sustained elevation of GH and IGF-1. Dr. Teichman's scholarly contributions have substantially advanced peptide endocrinology and the development of extended-duration hormonal agents.

Research Collaborations and Academic Output

Dr. Stuart L. Teichman has centered his investigation career on examining GH secretion-stimulating peptides, GHRH analog compounds, and peptide-based regulation of endocrine function. In collaboration with distinguished researchers A. Neale, B. Lawrence, and C. Gagnon, Dr. Teichman has assembled extensive peer-reviewed publications exploring the biochemical basis of extended-action GHRH peptides, their impact on GH/IGF-1 regulatory mechanisms, and their broad metabolic ramifications. His consolidated scientific publications establish a critical foundation for development of next-generation peptide-based pharmaceuticals aimed at equilibrating endocrine function and enhancing metabolic wellness.

This acknowledgment is presented for the sole purpose of scientific attribution and should not be construed as organizational endorsement, promotional communication, or professional partnership. Montreal Peptides Canada declares no business collaboration, funding relationship, or collegial association with Dr. Teichman or any named co-workers.

Cited Scientific References

Teichman SL, Neale A, Lawrence B, Gagnon C, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/

Broglio F, et al. Growth hormone secretagogues: clinical perspectives and safety concerns. Growth Horm IGF Res. 2009;19(1):1-9. https://pubmed.ncbi.nlm.nih.gov/19054601/

Ghigo E, et al. Growth hormone secretagogues: physiology and clinical applications. Endocr Rev. 2005;26(3):345-376. https://pubmed.ncbi.nlm.nih.gov/15814849/

Anderson-Baucum EK, et al. GH/IGF-1 axis and metabolic regulation. Mol Cell Endocrinol. 2018;469:1-14. https://pubmed.ncbi.nlm.nih.gov/29288913/

Wu Z, et al. Growth hormone and IGF-1 signaling in muscle metabolism. Front Endocrinol (Lausanne). 2020;11:607. https://pubmed.ncbi.nlm.nih.gov/33281526/

Ranke MB, Wit JM. Growth hormone-past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300. https://pubmed.ncbi.nlm.nih.gov/29479014/

Strasburger CJ, et al. GH and IGF-1 in clinical practice: new insights. Eur J Endocrinol. 2021;185(6):R123-R136. https://pubmed.ncbi.nlm.nih.gov/34870144/

Smith TR, et al. The role of GH and IGF-1 in tissue repair and regeneration. Exp Gerontol. 2015;68:46-52. https://pubmed.ncbi.nlm.nih.gov/25987250/